Showing 1511-1520 of 5771 results for "".
- Visus Therapeutics Announces New Scientific Data to Be Presented at ARVO 2023https://modernod.com/news/visus-therapeutics-announces-new-scientific-data-to-be-presented-at-arvo-2023/2481541/Visus Therapeutics announced it will present new scientific data at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, to be held April 23-27, 2023 in New Orleans. The presentations will highlight new research findings on the company’s alpha-cryst
- Vialase Announces 24-Month Safety Data from First-in-Human Study of Femtosecond Laser Image-Guided High-Precision Trabeculotomy (FLigHT)https://modernod.com/news/vialase-announces-publication-of-24-month-safety-data-from-first-in-human-study-of-femtosecond-laser-image-guided-high-precision-trabeculotomy-flight/2481538/ViaLase announced the online publication of 24-month safety data from the first-in-human study of femtosecond laser image-guided high-precision trabeculotomy (FLigHT) performed with the ViaLase technolo
- Trefoil Therapeutics Announces TTHX1114 Data Presentations at the ARVO 2023https://modernod.com/news/trefoil-therapeutics-announces-tthx1114-data-presentations-at-the-arvo-2023/2481536/Trefoil Therapeutics announced multiple presentations providing evidence for clinical and preclinical efficacy of the company’s investigational medicine TTHX1114 for improving visual outcomes and protection against corneal endothelial damage at the Annual Association for Research in Vision
- Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of Gene Therapy OCU400, for the Treatment of RP and LCAhttps://modernod.com/news/ocugen-announces-positive-preliminary-safety-and-efficacy-results-from-the-phase-12-trial-of-gene-therapy-ocu400-for-the-treatment-of-rp-and-lca/2481534/Ocugen announced positive preliminary data among retinitis pigmentosa (RP) participants treated in the first two cohorts of the phase 1/2 trial to assess the safety and efficacy of OCU400 for RP associated with NR2E3 and Rhodopsin (RHO) mutations and Leber Congenital Amaurosis (LCA) wit
- Nova Eye Medical Announces US Market Clearance of the iTrack Advance Canaloplasty Devicehttps://modernod.com/news/nova-eye-medical-announces-us-market-clearance-of-the-itrack-advance-canaloplasty-device/2481530/Nova Eye Medical announced that it has been granted FDA 510(k) clearance for its new canaloplasty device, iTrack Advance. The iTrack Advance has been cleared for microcatheterization and viscodilation to reduce IOP in adult patients with prim
- Aviceda Announces FDA Clearance of the IND Application Enabling Phase 2 Trials for GA Drug Candidatehttps://modernod.com/news/aviceda-announces-fda-clearance-of-the-ind-application-enabling-phase-2-trials-for-geographic-atrophy-drug-candidate/2481529/Aviceda Therapeutics announced that the FDA has cleared the IND for AVD-104, enabling the company to proceed with initiating phase 2 clinical trials of its lead intravitreal ocular asset for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The Pha
- Atsena Therapeutics Announces 6-Month Data from Phase 1/2 Clinical Trial of ATSN-101 to be Presented at ARVOhttps://modernod.com/news/atsena-therapeutics-announces-6-month-data-from-phase-12-clinical-trial-of-atsn-101-to-be-presented-at-arvo/2481523/Atsena Therapeutics announced that 6-month safety and efficacy data from the ongoing phase 1/2 clinical trial of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1) will be presented at the Association for Research in Vision and Ophthalmol
- Lumata Health and Prevent Blindness Announce Partnership Aimed at Delivering More Resources to Americans with Vision Losshttps://modernod.com/news/lumata-health-and-prevent-blindness-announce-partnership-aimed-at-delivering-more-resources-to-americans-with-vision-loss/2481522/Lumata Health announced a partnership with Prevent Blindness which will focus on various initiatives to address barriers to care for patients, with a strong focus on mental health resources to start. “Our care coordinators are in frequent contact with pati
- Nidek Announces the Winners of the 3rd Annual Images of the Year Awardhttps://modernod.com/news/nidek-announces-the-winners-of-the-3rd-annual-images-of-the-year-award/2481521/Nidek has announced the winners of the 3rd Annual Images of the Year Award. While continuing the theme “invisible to visible,” this year’s contest highlighted how multiple imaging techniques of the Mirante Scanning Laser Ophthalmoscope (NIDEK) helps retina specialists visua
- First Myopia Action Month Announced for Septemberhttps://modernod.com/news/first-myopia-action-month-announced-for-september/2481510/Myopia Profile announced its launch of Myopia Action Month to channel myopia awareness into action. Taking place in September, the inaugural event is designed to bring 4 weeks of global education, industry collaboration, and encouragement to ECPs to empower them to take effect